248 related articles for article (PubMed ID: 35108662)
41. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
Jiang T; Wang G; Liu Y; Feng L; Wang M; Liu J; Chen Y; Ouyang L
Acta Pharm Sin B; 2021 Feb; 11(2):355-372. PubMed ID: 33643817
[TBL] [Abstract][Full Text] [Related]
42. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
43. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
Aref-Eshghi E; Lin F; Li MM; Zhong Y
Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
[TBL] [Abstract][Full Text] [Related]
44. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
45. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract][Full Text] [Related]
46. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
Laetsch TW; Hong DS
Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
[TBL] [Abstract][Full Text] [Related]
47. Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma.
Simmons C; Deyell RJ; MacNeill AJ; Vera-Badillo FE; Smrke A; Abdul Razak AR; Banerji S; McLeod D; Noujaim J
Int J Cancer; 2021 Nov; 149(9):1691-1704. PubMed ID: 34213775
[TBL] [Abstract][Full Text] [Related]
48. NTRK insights: best practices for pathologists.
Hechtman JF
Mod Pathol; 2022 Mar; 35(3):298-305. PubMed ID: 34531526
[TBL] [Abstract][Full Text] [Related]
49. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer.
Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM
Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589
[TBL] [Abstract][Full Text] [Related]
50. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
[TBL] [Abstract][Full Text] [Related]
51. NTRK point mutations and their functional consequences.
Rogers C; Morrissette JJD; Sussman RT
Cancer Genet; 2022 Apr; 262-263():5-15. PubMed ID: 34972036
[TBL] [Abstract][Full Text] [Related]
52. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.
Zhou KI; Vashistha V; Guo A; Ahmed S; Kelley MJ
JCO Precis Oncol; 2023 Mar; 7():e2200692. PubMed ID: 36926986
[TBL] [Abstract][Full Text] [Related]
53. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
54. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
55. NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma.
Wang Y; Long P; Wang Y; Ma W
Front Oncol; 2020; 10():593578. PubMed ID: 33330081
[TBL] [Abstract][Full Text] [Related]
56. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
57. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
Garrido P; Hladun R; de Álava E; Álvarez R; Bautista F; López-Ríos F; Colomer R; Rojo F
Clin Transl Oncol; 2021 Aug; 23(8):1529-1541. PubMed ID: 33620682
[TBL] [Abstract][Full Text] [Related]
58. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
59. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Doz F; van Tilburg CM; Geoerger B; Højgaard M; Øra I; Boni V; Capra M; Chisholm J; Chung HC; DuBois SG; Gallego-Melcon S; Gerber NU; Goto H; Grilley-Olson JE; Hansford JR; Hong DS; Italiano A; Kang HJ; Nysom K; Thorwarth A; Stefanowicz J; Tahara M; Ziegler DS; Gavrilovic IT; Norenberg R; Dima L; De La Cuesta E; Laetsch TW; Drilon A; Perreault S
Neuro Oncol; 2022 Jun; 24(6):997-1007. PubMed ID: 34850167
[TBL] [Abstract][Full Text] [Related]
60. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
